Published by The New Angle on March 27, 2026
March 27th, 2026
Do you ever consider how the economy of Britain is performing? Do you consider what this means for your country and perhaps your savings, wages, mortage payments, rent prices?
Here we have a single insight that could give you a rough idea.
Britain's largest public company is AstraZeneca, which you may remember from the COVID-19 pandemic. They were responsible for producing one of the COVID-19 vaccines. We ought to consider it a national treasure, given the jobs it produces and the boon it brings to the United Kingdom, and as a reflection of our pharmacautical and bioscience excellence.
It was founded in 1999 after a merger between the Swedish pharmaceutical company Astra AB, and the British pharmaceutical company Zeneca Group PLC. The company is listed for public ownership on the London Stock Exchange, the Swedish Nasdaq Stockholm, and the New York Stock Exchange.
Recent performance shows -11% in stock price in the past month, +0.3% increase starting from January 2026, +27% increase in the past 12 months, and +86% increase in the past five years as of today's date. This shows weak performance since the start of the new year, but good overall performance in the past 12 months.
They are primarily head-quartered in Cambridge, England. However, they have Research & Development offices in Maryland USA, Gothenburg Sweden, Boston Massachussetts, as well as presence in Shangai and Beijing. Their commercial HQ for North America is in Delaware USA.
Recent expansion has prioritised the USA as a location, including manufacturing facillities in Texas, Indiana, and especially Maryland. In Europe, manufacturing occurs in Speke England, Sweden, and Netherlands. There are also facillities in China.
The company employs 90,000 people worldwide, with primary focus in Britain, America, and Sweden.
You may also remember that in collaboration with the Jenner Institute and the Oxford Vaccine Group of Oxford University, AstraZeneca produced one of the COVID-19 vaccines alongside Pfizer at excellent and unparalleled speed.
AstraZeneca is symbolic of Britain's strength as a biomedical and pharmaceutical power. The market capitalisation, that is the value of the company, is around $284-287 billion as of today's date. This makes it the most valuable public company in Britain.
And here is the key economic insight we'd like to make you aware of. If AstraZeneca, our best company, were in America, it would be the 37th largest company. In China, it would be 7th. In Japan it would be 2nd. In France, it would be 1st or 2nd. For every other European country, it would be the most valuable public company. For India, it would be 1st.
This shows the relative advantage of Britain over most of the world. It also shows the unparalleled might of America. Our greatest company would land at a measly 37th in the list of American companies. We are also behind China, though not so far. And our performance by this metric is similar to Japan and France.
If we follow the Pareto principle, that most of our wealth aggregates at the top 1%, then we ought to give greater consideration to the top 1% of Britain's great companies. Let us also consider the inexorbitant quantity of tax AstraZeneca likely pays into the economy of Britain.
We ought to consider AstraZeneca a national treasure. And we ought to be inspired to create more excellent companies of the sort.